Biodel Inc.l Reports Positive Top-Line Results From Clinical Study of Ultra-Rapid-Acting Insulin Analog Candidates

January 24, 2013 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

DANBURY, Conn., Jan. 24, 2013 (GLOBE NEWSWIRE) -- In a release issued earlier today by Biodel Inc. (Nasdaq:BIOD), one reference to BIOD-238 should have been BIOD-250 in the fourth paragraph. The corrected paragraph follows:

Twitter
LinkedIn
Facebook
Email
Print